For the year ending 2025-12-31, SKYE had -$62,533,243 decrease in cash & cash equivalents over the period. -$43,068,841 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -55,924,814 |
| Write-down of vendor deposits | 0 |
| Depreciation and amortization | 723,352 |
| Net loss on disposal of asset | 0 |
| Stock-based compensation expense | 7,767,694 |
| Amortization of debt discount | 0 |
| Change in estimate for legal contingencies | 0 |
| Gain from asset sale | 360,750 |
| Prepaid expenses | 302,928 |
| Other current assets | -1,357,508 |
| Other assets | 0 |
| Accounts payable | 1,395,428 |
| Accrued interest related party-Related Party | 0 |
| Accrued interest related party-Nonrelated Party | 0 |
| Accrued payroll liabilities | 155,219 |
| Other current liabilities | 2,308,706 |
| Operating lease liability | -181,944 |
| Net cash, cash equivalents used in operating activities | -43,062,529 |
| Proceeds from asset sales, net of legal expenses | 360,750 |
| Purchase of short-term investment | 19,854,723 |
| Purchases of property and equipment | 6,312 |
| Net cash, and cash equivalents used in investing activities | -19,500,285 |
| Proceeds from warrant exercises | 0 |
| Purchase under employee stock purchase plan | 29,571 |
| Proceeds from option exercises | 0 |
| Net cash, and cash equivalents provided by financing activities | 29,571 |
| Net increase in cash and cash equivalents | -62,533,243 |
| Cash, cash equivalents, beginning of year | 68,415,741 |
| Cash, cash equivalents, end of year | 5,882,498 |
Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc. (SKYE)